Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totalling 900 shares, a decrease of 98.5% from the March 31st total of 60,400 shares. Based on an average daily trading volume, of 885,400 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are short sold.

Astellas Pharma Price Performance

ALPMY stock traded up $0.02 during trading on Tuesday, hitting $10.08. The company had a trading volume of 77,003 shares, compared to its average volume of 223,883. The company has a market cap of $18.24 billion, a P/E ratio of -45.82 and a beta of 0.31. The company has a fifty day moving average price of $9.61 and a two-hundred day moving average price of $10.03. Astellas Pharma has a fifty-two week low of $8.37 and a fifty-two week high of $13.14. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last announced its earnings results on Friday, April 25th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.15 by $0.12. The company had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.02 billion. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. Equities research analysts expect that Astellas Pharma will post 0.42 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.